ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc (AGIO)

28,29
-0,50
(-1,74%)
Geschlossen 08 Juni 10:00PM
28,29
-0,005
(-0,02%)
Nach Börsenschluss: 1:59AM

Agios Pharmaceuticals Inc (AGIO) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
28,29
( -1,74% )
Gebot
20,85
Fragen
37,11
Volumen
561.352
28,13 Tagesbereich 29,39
22,24 52-Wochen-Bereich 46,00
Marktkapitalisierung
Handelsende
28,79
Handelsbeginn
28,95
Letzte Trade
74
@
27.73
Letzter Handelszeitpunkt
Finanzvolumen
US$ 16.058.452
VWAP
28,6067
Durchschnittliches Volumen (3 Mio.)
US$ 1.047.304
Ausgegebene Aktien
59.471.609
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-3,82
Gewinn pro Aktie (EPS)
-7,25
Erlöse (LTM)
66,05M
Nettogewinn (LTM)
-422,6M

Über Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic ... Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Cambridge, United States
Gegründet
2026
Agios Pharmaceuticals Inc is listed in the Healthcare sector of the NASDAQ with ticker AGIO. The last closing price for Agios Pharmaceuticals was US$28,79. Over the last year, Agios Pharmaceuticals shares have traded in a share price range of US$ 22,24 to US$ 46,00.

Agios Pharmaceuticals currently has 59.471.609 shares in issue. The market capitalisation of Agios Pharmaceuticals is US$1,68 billion. Agios Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.82.

AGIO Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.8-2.7500859401929.0930.2826.4494321328.14039358CS
40.792.8727272727327.530.5326.4479942728.40539323CS
120.531.9092219020227.7636.3524.29104770229.32286015CS
260.732.6487663280127.5636.3524.16104722428.49459296CS
52-5.72-16.818582769834.014622.24101502130.95544921CS
1562.479.5662277304425.8262.5819.79576994532.54441846CS
260-29.38-50.945032079157.6762.5816.7570216832.53244822CS

AGIO - Frequently Asked Questions (FAQ)

What is the current Agios Pharmaceuticals Inc share price?
The current share price of Agios Pharmaceuticals Inc is US$ 28,29
How many Agios Pharmaceuticals Inc shares are in issue?
Agios Pharmaceuticals Inc has 59.471.609 shares in issue
What is the market cap of Agios Pharmaceuticals Inc?
The market capitalisation of Agios Pharmaceuticals Inc is USD 1,68B
What is the 1 year trading range for Agios Pharmaceuticals Inc share price?
Agios Pharmaceuticals Inc has traded in the range of US$ 22,24 to US$ 46,00 during the past year
What is the PE ratio of Agios Pharmaceuticals Inc?
The price to earnings ratio of Agios Pharmaceuticals Inc is -3,82
What is the cash to sales ratio of Agios Pharmaceuticals Inc?
The cash to sales ratio of Agios Pharmaceuticals Inc is 24,92
What is the registered address of Agios Pharmaceuticals Inc?
The registered address for Agios Pharmaceuticals Inc is 88 Sidney Street, Cambridge, Massachusetts, 02139
What is the Agios Pharmaceuticals Inc website address?
The website address for Agios Pharmaceuticals Inc is www.agios.com
Which industry sector does Agios Pharmaceuticals Inc operate in?
Agios Pharmaceuticals Inc operates in the Biotechnology & Life Sciences sector

AGIO Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen